CTOs on the Move


 
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.oramed.com
  • 1185 Avenue of the Americas 3rd Floor
    New York, NY USA 10036
  • Phone: 646.844.1164

Executives

Name Title Contact Details

Funding

Oramed raised $50M on 11/03/2021

Similar Companies

Wellinks

Wellinks is a virtual COPD management solution empowering members to live fully, and breathe freely.

Prometheus Laboratories

Prometheus Laboratories Inc. is one of the leading companies in the Healthcare, Pharmaceuticals and Biotech sector.

Duramed Pharmaceuticals

Duramed Pharmaceuticals is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vilex

Vilex is an innovative manufacturer of orthopaedic internal and external fixation devices, plates, and small joint implants.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.